+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Liraglutide"

Non-Insulin Therapies for Diabetes Market Report 2025 - Product Thumbnail Image

Non-Insulin Therapies for Diabetes Market Report 2025

  • Report
  • April 2025
  • 200 Pages
  • Global
From
From
Diabetes Drugs - Global Strategic Business Report - Product Thumbnail Image

Diabetes Drugs - Global Strategic Business Report

  • Report
  • August 2025
  • 196 Pages
  • Global
From
Anti-Obesity Drugs - Global Strategic Business Report - Product Thumbnail Image

Anti-Obesity Drugs - Global Strategic Business Report

  • Report
  • August 2025
  • 264 Pages
  • Global
From
From
Obesity - Pipeline Insight, 2025 - Product Thumbnail Image

Obesity - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 240 Pages
  • Global
From
Anti-Obesity Drugs Market Report and Forecast 2025-2034 - Product Thumbnail Image

Anti-Obesity Drugs Market Report and Forecast 2025-2034

  • Report
  • June 2025
  • 400 Pages
  • Global
From
Type 2 Diabetes Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Type 2 Diabetes Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
GLP-1 Agonists Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

GLP-1 Agonists Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
From
Obesity Market Report and Forecast 2025-2034 - Product Thumbnail Image

Obesity Market Report and Forecast 2025-2034

  • Report
  • June 2025
  • 400 Pages
  • Global
From
Diabetes Drug Market Overview, 2025-30 - Product Thumbnail Image

Diabetes Drug Market Overview, 2025-30

  • Report
  • June 2025
  • 109 Pages
  • Global
From
Abnormal Glucose Tolerance- - Pipeline Insight, 2025 - Product Thumbnail Image

Abnormal Glucose Tolerance- - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
From
From
Asia-Pacific Diabetes Drug Market Outlook, 2030 - Product Thumbnail Image

Asia-Pacific Diabetes Drug Market Outlook, 2030

  • Report
  • June 2025
  • 97 Pages
  • Asia Pacific
From
From
Loading Indicator

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used as an anti-obesity drug. It is a long-acting analogue of human GLP-1, a hormone that is released in response to food intake. Liraglutide works by stimulating the release of insulin and suppressing appetite. It is typically prescribed as an adjunct to diet and exercise for the treatment of obesity. It is also used to treat type 2 diabetes. Liraglutide is available in both injectable and oral formulations. The injectable form is administered subcutaneously once daily, while the oral form is taken once daily with food. Common side effects of liraglutide include nausea, vomiting, diarrhea, and abdominal pain. Several companies are involved in the liraglutide market, including Novo Nordisk, Eli Lilly, Sanofi, and Merck. Show Less Read more